natgillin/translations-raw huggingface dataset:
Hospitalisation is advised and general supportive measures should be employed with immediate gastric lavage and repeated doses of charcoal over time.
Svetuje se hospitalizacija s splošnimi podpornimi ukrepi, takojšnjim izpiranjem želodca in večkratnimi odmerki aktivnega oglja v času zdravljenja.
BOTTLE LABEL AND OUTER CARTON TEXT
NALEPKA NA STEKLENIČKI IN BESEDILO NA ZUNANJI OVOJNINI
- Entacapone in association with levodopa has been associated with somnolence and episodes of sudden sleep onset in patients with Parkinson's disease and caution should therefore be exercised when driving or operating machines (see section 4.7).
- Entakapon v kombinaciji z levodopo povezujejo s pojavom zaspanosti in nenadnega spanca pri bolnikih s Parkinsonovo boleznijo, zaradi česar je potrebna previdnost pri vožnji in upravljanju strojev (glejte poglavje 4.7).
*Adverse reactions that are mainly attributable to entacapone or are more frequent (by the frequency difference of at least 1% in the clinical trial data) with entacapone than levodopa/DDC inhibitor alone.
*Neželeni učinki, ki se v glavnem pripisujejo entakaponu ali so z entakaponom pogostejši (z razliko v pogostnosti vsaj 1 % po podatkih iz kliničnih preskušanj) kot samo z levodopo/zaviralcem dekarboksilaze.
- Patients with chronic wide-angle glaucoma may be treated with Levodopa/Carbidopa/Entacapone Orion with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.
- Bolniki s kroničnim glavkomom odprtega zakotja se ob primerni previdnosti lahko zdravijo z zdravilom Levodopa/Carbidopa/Entacapone Orion, pod pogojem, da je intraokularni tlak dobro obvladovan in da bolnika skrbno spremljamo, če bi se pojavile spremembe v intraokularnem tlaku.
MAO-B inhibitors, or non-selective MAO-inhibitors) - have ever had neuroleptic malignant syndrome (NMS - this is a rare reaction to medicines used to treat severe mental disorders) - have ever had non-traumatic rhabdomyolysis (a rare muscle disorder) - have a severe liver disease.
MAO-A in MAO-B ali neselektivne zaviralce MAO); - če ste že kdaj imeli maligni nevroleptični sindrom (NMS - to je redka reakcija na zdravila, ki se uporabljajo za zdravljenje hudih duševnih motenj); - če ste že kdaj imeli netravmatsko rabdomiolizo (redko obolenje mišic); - če imate hudo bolezen jeter.
Tell your doctor if you or your family/carer notices you are developing addiction-like symptoms leading to craving for large doses of Levodopa/Carbidopa/Entacapone Orion and other medicines used to treat Parkinson's disease.
Obvestite zdravnika, če vi ali kdo od družinskih članov/negovalec opazi(te), da se pri vas razvijajo simptomi, podobni odvisnosti, ki vodijo do potrebe po velikih odmerkih zdravila Levodopa/Carbidopa/Entacapone Orion in drugih zdravil za zdravljenje Parkinsonove bolezni.
Levodopa/Carbidopa/Entacapone Orion is not recommended to be used for treatment of extrapyramidal symptoms (e.g. involuntary movements, shaking, muscle rigidity and muscle contractions) caused by other medicines.
Zdravilo Levodopa/Carbidopa/Entacapone Orion se ne priporoča za zdravljenje ekstrapiramidnih simptomov (npr. nehotnih gibov, tremorja, otrdelosti mišic in mišičnih kontrakcij), ki jih povzročajo druga zdravila.
When decarboxylation of levodopa is reduced with the co-administration of a DDC inhibitor, a lower dose of levodopa can be used and the incidence of adverse reactions such as nausea is reduced.
Kadar se dekarboksilacija levodope zmanjša s pomočjo sočasne uporabe zaviralca DDK, se lahko uporabi manjši odmerek levodope, s tem pa se zmanjša incidenca neželenih učinkov, kot je npr. bruhanje.
Levodopa/Carbidopa/Entacapone Orion may lower your blood pressure, which may make you feel light-headed or dizzy.
Zdravilo Levodopa/Carbidopa/Entacapone Orion lahko zniža vaš krvni tlak, zaradi česar se boste počutili vrtoglavi in omotični.
- In patients with a history of myocardial infarction who have residual atrial nodal or ventricular arrhythmias; cardiac function should be monitored with particular care during the period of initial dose adjustments.
- Pri bolnikih z anamnezo miokardnega infarkta, ki imajo rezidualne preddvorne nodalne ali prekatne motnje srčnega ritma, je treba delovanje srca še posebej skrbno spremljati v obdobju prilagajanja začetnega odmerka.
Dopamine does not cross the blood-brain barrier.
Dopamin ne prehaja skozi krvnomožgansko pregrado.
- If general anaesthesia is required, therapy with Levodopa/Carbidopa/Entacapone Orion may be continued for as long as the patient is permitted to take fluids and medicinal products by mouth.
- Če je potrebna splošna anestezija, se lahko terapija z zdravilom Levodopa/Carbidopa/Entacapone Orion nadaljuje vse dokler sme bolnik jemati tekočine in zdravila peroralno.
Paediatric population: The safety and efficacy of Levodopa/Carbidopa/Entacapone Orion in children aged below 18 years have not been established.
Pediatrična populacija: Varnost in učinkovitost zdravila Levodopa/Carbidopa/Entacapone Orion pri otrocih starih do 18 let nista bili dokazani.
A significant number of Parkinson's disease patients have been treated with the combination of levodopa, carbidopa and entacapone with several active substances including MAO-A inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine and medicinal products that are metabolised by COMT (e.g. catechol-structured compounds, paroxetine).
Znatno število bolnikov s Parkinsonovo boleznijo so zdravili s kombinacijo levodope, karbidope in entakapona ter mnogimi učinkovinami, vključno z zaviralci MAO-A, tricikličnimi antidepresivi, zaviralci ponovnega privzema noradrenalina, kot so dezipramin, maprotilin in venlafaksin, ter zdravila, ki se presnavljajo preko COMT (npr. učinkovine, ki imajo v svoji strukturi katehol, paroksetin).
You should be aware that Levodopa/Carbidopa/Entacapone Orion may make these reactions worse.
Zavedati se morate, da lahko zdravilo Levodopa/Carbidopa/Entacapone Orion te reakcije še poslabša.
Interactions between entacapone and selegiline have been investigated in repeated dose studies in Parkinson's disease patients treated with levodopa/DDC inhibitor and no interaction was observed.
Interakcije med entakaponom in selegilinom so proučevali v raziskavah z večkratnimi odmerki pri bolnikih s Parkinsonovo boleznijo, ki so bili zdravljeni z levodopo/zaviralci DDK in niso ugotovili nobenih interakcij.
The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Levodopa/Carbidopa/Entacapone Orion or entacapone combined with levodopa/DDC inhibitor, and 1420 treated with placebo combined with levodopa/DDC inhibitor or cabergoline combined with levodopa/ DDC inhibitor), and from the post-marketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa/DDC inhibitor.
Neželeni učinki v nadaljevanju, našteti v preglednici 1, so bili zbrani iz združenih podatkov enajstih dvojno slepih kliničnih preskušanj, ki so zajela 3.230 bolnikov (1.810 zdravljenih z zdravilom Levodopa/Carbidopa/Entacapone Orion ali entakaponom v kombinaciji z levodopo/zaviralcem dekarboksilaze, in 1.420 zdravljenih s placebom v kombinaciji z levodopo/zaviralcem dekarboksilaze ali kabergolinom v kombinaciji z levodopo/zaviralcem dekarboksilaze), in iz podatkov v obdobju trženja, od uvedbe entekapona za kombinirano uporabo z levodopo/zaviralcem dekarboksilaze.
Biotransformation and elimination: Levodopa is extensively metabolised to various metabolites: decarboxylation by dopa decarboxylase (DDC) and O-methylation by catechol-O-methyltransferase (COMT) being the most important pathways.
Biotransformacija in izločanje: Levodopa se v veliki meri presnavlja v različne presnovke, pri čemer sta najpomembnejši presnovni poti dekarboksilacija z dopa dekarboksilazo (DDK) in O-metilacija s katehol-O-metiltransferazo (COMT).
However, a direct switch from levodopa/DDC inhibitor to Levodopa/Carbidopa/Entacapone Orion is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 800 mg.
Neposreden prehod z levodope/zaviralcev DDK na zdravilo Levodopa/Carbidopa/Entacapone Orion pa ni priporočljiv pri bolnikih z diskinezijo ali pri tistih z dnevnim odmerkom levodope nad 800 mg.
As part of this PSUSA procedure, update of the levodopa/carbidopa/entacapone SmPCs with identical changes regarding dopamine dysregulation syndrome as agreed previously by the CMDh in the PSUSA process for levodopa/carbidopa containing products is considered warranted.
Kot del tega postopka PSUSA je upravičena posodobitev SmPC-jev levodope/karbidope/entakapona z enakimi spremembami glede sindroma motene regulacije dopamina, kot je bilo prej dogovorjeno s CMDh v postopku PSUSA za zdravila, ki vsebujejo levodopo/karbidopo.
Not known (cannot be estimated from the available data) Craving for large doses of Levodopa/Carbidopa/Entacapone Orion in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome.
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) Potreba po visokih odmerkih zdravila Levodopa/Carbidopa/Entacapone Orion, ki presegajo odmerek, ustrezen za obvladovanje motoričnih simptomov, ki se imenuje sindrom motene regulacije dopamina.
Levodopa and entacapone may form chelates with iron in the gastrointestinal tract.
Levodopa in entakapon lahko v prebavnem traktu tvorita kelate z železom.
NMS, including rhabdomyolysis and hyperthermia, is characterised by motor symptoms (rigidity, myoclonus, tremor), mental status changes (e.g., agitation, confusion, coma), hyperthermia, autonomic dysfunction (tachycardia, labile blood pressure) and elevated serum creatine phosphokinase.
Za NMS, vključno z rabdomiolizo in hipertermijo, so značilni motorični simptomi (otrplost, mioklonus, tresenje), spremembe duševnega stanja (npr. vznemirjenost, zmedenost, koma), hipertermija, disfunkcija avtonomnega živčevja (tahikardija, labilen krvni tlak) in povišana vrednost serumske kreatin fosfokinaze.
Entacapone enhances the effects of levodopa.
Entakapon poveča učinek levodope.
Antidepressants: Rarely, reactions including hypertension and dyskinesia have been reported with the concomitant use of tricyclic antidepressants and levodopa/carbidopa.
Antidepresivi: Redka poročila navajajo reakcije, ki vključujejo hipertenzijo in diskinezijo v povezavi s sočasno uporabo tricikličnih antidepresivov in levodope/karbidope.
When used with Levodopa/Carbidopa/Entacapone Orion, the daily dose of selegiline should not exceed 10 mg.
Ob sočasni uporabi z zdravilom Levodopa/Carbidopa/Entacapone Orion skupni dnevni odmerek selegilina ne sme presegati 10 mg.
Dopamine dysregulation syndrome (DDS) is described as a compulsive pattern of dopaminergic misuse above doses adequate to control motor symptoms.
Sindrom motene regulacije dopamina (DDS) je opisan kot kompulzivna oblika zlorabe dopaminergičnih zdravil z odmerki, večjimi od tistih, ki so ustrezni za obvladovanje motoričnih simptomov.
Detailed information on this medicinal product is available on the website of European Medicines Agency: http://www.ema.europa.eu.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
Preclinical data of levodopa, carbidopa and entacapone, tested alone or in combination, revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.
Predklinični podatki za levodopo, karbidopo in entakapon bodisi samostojno ali v kombinaciji, ki so temeljili na standardnih študijah farmakološke varnosti, toksičnosti ponavljajočih se odmerkov, genotoksičnosti ali karcinogenosti, niso pokazali posebnega tveganja za človeka.
Your doctor may take some regular laboratory tests during a long term treatment with Levodopa/Carbidopa/Entacapone Orion.
Zdravnik lahko izvede nekaj rednih laboratorijskih preiskav med dolgoročnim zdravljenjem z zdravilom Levodopa/Carbidopa/Entacapone Orion.
There are no adequate data from the use of the combination of levodopa/carbidopa/entacapone in pregnant women.
Podatkov o uporabi kombinacije levodope/karbidope/entakapona pri nosečnicah ni.
Other forms of interactions: Since levodopa competes with certain amino acids, the absorption of Levodopa/Carbidopa/Entacapone Orion may be impaired in some patients on high protein diet.
Druge oblike interakcij: Ker levodopa tekmuje (kompetitira) z nekaterimi aminokislinami, je lahko pri nekaterih bolnikih, ki uživajo visoko proteinsko dieto, absorpcija zdravila Levodopa/Carbidopa/Entacapone Orion motena.
Levodopa/Carbidopa/Entacapone Orion may have a major influence on the ability to drive and use machines.
Zdravilo Levodopa/Carbidopa/Entacapone Orion ima pomemben vpliv na sposobnost vožnje in upravljanja strojev.
150 mg/37.5 mg/200 mg tablets, do not take more than 10 tablets per day.
150 mg/37,5 mg/200 mg tablete, ne vzemite več kot 10 tablet dnevno.
Constipation*, vomiting*, dyspepsia, abdominal pain and discomfort*, dry mouth*
zaprtost*, bruhanje*, dispepsija, abdominalni trebuh in nelagodje*, suha usta*
Because the effects of Levodopa/Carbidopa/Entacapone Orion tablets are equivalent with entacapone 200 mg tablet administered concomitantly with the commercially available standard release carbidopa/levodopa preparations in corresponding doses these results are applicable to describe the effects of Levodopa/Carbidopa/Entacapone Orion as well.
Ker so učinki tablet zdravila Levodopa/Carbidopa/Entacapone Orion enaki kot pri tabletah entakapona 200 mg, uporabljenih sočasno z zdravili karbidope/levodope s standardnim sproščanjem v odgovarjajočih odmerkih, so ti rezultati uporabni tudi za prikaz učinkov zdravila Levodopa/Carbidopa/Entacapone Orion.
Therefore, do not take Levodopa/Carbidopa/Entacapone Orion and iron supplements at the same time.
Zato ne jemljite zdravila Levodopa/Carbidopa/Entacapone Orion in železovih dodatkov sočasno.
Other antiparkinsonian medicinal products: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Levodopa/Carbidopa/Entacapone Orion therapy.
Drugi antiparkinsoniki: Do sedaj niso znane nobene interakcije, ki bi omejevale sočasno uporabo standardnih antiparkinsonikov in zdravila Levodopa/Carbidopa/Entacapone Orion.
Very common (may affect more than 1 in 10 people) - uncontrolled movements (dyskinesias) - feeling sick (nausea) - harmless reddish-brown discolouration of urine - muscle pain - diarrhoea
Zelo pogosti neželeni učinki (lahko se pojavijo pri več kot 1 od 10 bolnikov): - nekontrolirani gibi (diskinezije) - slabost (navzea) - neškodljivo rdečkastorjavo obarvanje urina - bolečina mišic - driska
- a liver problem, because your dose may need to be adjusted - kidney or hormone-related diseases - stomach ulcers or convulsions - if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon - any form of severe mental disorder like psychosis - chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored.
- bolezen ledvic, ali bolezni povezane s hormoni; - želodčno razjedo ali konvulzije (krče); - če pride do dolgotrajne driske, se posvetujte z zdravnikom, saj gre lahko za znak vnetja debelega črevesa; - kakršno koli obliko hude duševne motnje kot je psihoza; - če imate kronični glavkom odprtega zakotja, saj bo morda treba odmerek vašega zdravila prilagoditi in redno meriti vaš očesni tlak.
Entacapone in association with levodopa has been associated with isolated cases of excessive daytime somnolence and sudden sleep onset episodes.
Entakapon v povezavi z levodopo povezujejo s posameznimi primeri pretirane somnolence čez dan in epizod nenadnega spanja.
c. When initiating Levodopa/Carbidopa/Entacapone Orion in patients currently treated with entacapone and levodopa/benserazide in a standard release formulation, the dosing of levodopa/benserazide should be discontinued in the previous night, and Levodopa/Carbidopa/Entacapone Orion should be started in the next morning.
c. Ko se zdravljenje z zdravilom Levodopa/Carbidopa/Entacapone Orion uvaja pri bolnikih, ki trenutno prejemajo entakapon in levodopo/benzerazid s standardnim sproščanjem, je treba odmerjanje levodope/benzerazida eno noč ukiniti in naslednje jutro začeti dajati zdravilo Levodopa/Carbidopa/Entacapone Orion.
At the initiation, Levodopa/Carbidopa/Entacapone Orion should be adjusted to correspond as closely as possible to the total daily dose of levodopa currently used.
Ob uvedbi zdravljenja je treba zdravilo Levodopa/Carbidopa/Entacapone Orion prilagoditi tako, da kar najbolj odgovarja skupnemu do sedaj uporabljanemu dnevnemu odmerku levodope.
If you must undergo surgery, please tell your doctor that you are using Levodopa/Carbidopa/Entacapone Orion.
Če morate na operacijo, povejte svojemu zdravniku, da jemljete zdravilo Levodopa/Carbidopa/Entacapone Orion.
Patients taking these medicinal products with Levodopa/Carbidopa/Entacapone Orion should be carefully observed for loss of therapeutic response.
Bolnike, ki jemljejo ta zdravila poleg zdravila Levodopa/Carbidopa/Entacapone Orion, je treba skrbno spremljati zaradi morebitnega zmanjšanja terapevtskega odgovora.
How to transfer patients taking levodopa/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Levodopa/Carbidopa/Entacapone Orion a. Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Levodopa/Carbidopa/Entacapone Orion tablet strengths can be directly transferred to corresponding Levodopa/Carbidopa/Entacapone Orion tablets.
Kako preusmeriti bolnike, ki prejemajo levodopo/zaviralce DDK (karbidopo ali benzerazid) in entakapon tablete na zdravilo Levodopa/Carbidopa/Entacapone Orion a. Bolniki, ki trenutno prejemajo entakapon in levodopo/karbidopo s standardnim sproščanjem v odmerkih, ki po jakosti ustrezajo tabletam zdravila Levodopa/Carbidopa/Entacapone Orion, lahko neposredno preidejo na uporabo tablet zdravila Levodopa/Carbidopa/Entacapone Orion.
MARKETING AUTHORISATION NUMBER(S)
ŠTEVILK(E) DOVOLJENJ(A) ZA PROMET
Few adverse reactions are known to be directly attributable to the active substance entacapone including diarrhoea and reddish-brown discolouration of urine.
Znano je, da se lahko nekateri neželeni učinki pripišejo neposredno učinkovini entakapon, vključno z drisko in rdečkasto-rjavkastim obarvanjem urina.
Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease.
Levodopa, prekurzor v sintezi dopamina, prehaja skozi krvno-možgansko pregrado in lajša simptome bolezni.
Levodopa/Carbidopa/Entacapone Orion is used for the treatment of Parkinson's disease.
Zdravilo Levodopa/Carbidopa/Entacapone Orion se uporablja za zdravljenje Parkinsonove bolezni.
Muscle spasms, arthralgia
mišični spazmi, artralgija
Correspondingly, the decrease in daily OFF time was 24% in the entacapone group and 0% in the placebo group.
Skladno s tem se je dnevno trajanje intervala, ko zdravilo ni delovalo, (»OFF«) pri skupini z entakaponom skrajšalo za 24 %, pri skupini s placebom pa za 0 %.
If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines') - notice that uncontrolled movements begin or get worse after you started to take Levodopa/Carbidopa/Entacapone Orion.
Če se vam to zgodi, ne vozite in ne upravljajte strojev (glejte tudi poglavje »Vpliv na sposobnost upravljanja vozil in strojev«); - potem, ko ste začeli jemati zdravilo Levodopa/Carbidopa/Entacapone Orion, pojavijo nekontrolirani gibi, ali se ti pojavi poslabšajo.
Taking into account the PRAC Assessment Report on the PSUR for carbidopa/entacapone/levodopa, the scientific conclusions of the CHMP are as follows:
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za carbidopo/entakapon/levodopo je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
Levodopa/Carbidopa/Entacapone Orion and iron preparations should be taken at least 2-3 hours apart (see section 4.8).
Zato je treba pri jemanju zdravila Levodopa/Carbidopa/Entacapone Orion in železovih pripravkov upoštevati najmanj 2-3 urni razmak med obema zdraviloma (glejte poglavje 4.8).
Due to short elimination half-lives, no true accumulation of levodopa or entacapone occurs on repeated administration.
Zaradi kratkega razpolovnega časa izločanja ob ponovnih aplikacijah ne prihaja do večjega kopičenja levodope ali entakapona.
Discontinuation of Levodopa/Carbidopa/Entacapone Orion therapy: If Levodopa/Carbidopa/Entacapone Orion treatment (levodopa/carbidopa/entacapone) is discontinued and the patient is transferred to levodopa/DDC inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms.
Prekinitev zdravljenja z zdravilom Levodopa/Carbidopa/Entacapone Orion: Če je zdravljenje z zdravilom Levodopa/Carbidopa/Entacapone Orion (levodopa/karbidopa/entakapon) prekinjeno, bolnik pa namesto tega začne prejemati terapijo z levodopo/zaviralci DDK brez entakapona, je treba za dosego zadovoljive ravni obvladovanja parkinsonskih simptomov prilagoditi odmerjanje drugih antiparkinsonikov, zlasti levodope.
Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.
Z njim se lahko pogovorite o možnostih obvladovanja takega vedenja oziroma zdravljenja simptomov.
Therefore Levodopa/Carbidopa/Entacapone Orion should be given cautiously to patients who are taking other medicinal products which may cause orthostatic hypotension.
Zato je potrebna previdnost pri dajanju zdravila Levodopa/Carbidopa/Entacapone Orion bolnikom, ki jemljejo druga zdravila, ki lahko povzročajo ortostatsko hipotenzijo.
What Levodopa/Carbidopa/Entacapone Orion is and what it is used for What you need to know before you take Levodopa/Carbidopa/Entacapone Orion How to take Levodopa/Carbidopa/Entacapone Orion Possible side effects
Kaj je zdravilo Levodopa/Carbidopa/Entacapone Orion in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Levodopa/Carbidopa/Entacapone Orion Kako jemljati zdravilo Levodopa/Carbidopa/Entacapone Orion Možni neželeni učinki
How to transfer patients not currently treated with entacapone to Levodopa/Carbidopa/Entacapone Orion
Kako preusmeriti bolnike, ki trenutno ne prejemajo entakapona, na zdravilo Levodopa/Carbidopa/Entacapone Orion
Levodopa/Carbidopa/Entacapone Orion contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet.
Zdravilo Levodopa/Carbidopa/Entacapone Orion vsebuje tri učinkovine (levodopo, kabidopo in entakapon) v eni filmsko obloženi tableti.
If you suddenly stop taking of Levodopa/Carbidopa/Entacapone Orion and other antiparkinsonian medicines it may result in unwanted side effects.
Če boste nenadno prenehali jemati tablete zdravila Levodopa/Carbidopa/Entacapone Orion in druge antiparkinsonike, lahko doživite neželene učinke.
For example, a patient taking one tablet of 50 mg/12.5 mg of levodopa/carbidopa with one tablet of entacapone 200 mg four times daily can take one 50 mg/12.5 mg/200 mg Levodopa/Carbidopa/Entacapone Orion tablet four times daily in place of their usual levodopa/carbidopa and entacapone doses.
Na primer bolnik, ki prejema po eno tableto 50 mg/12,5 mg levodope/karbidope z eno tableto entakapona 200 mg 4-krat dnevno, lahko jemlje eno 50 mg/12,5 mg/200 mg tableto zdravila Levodopa/Carbidopa/Entacapone Orion 4-krat dnevno namesto običajnih odmerkov levodope/karbidope in entakapona.
Levodopa/Carbidopa/Entacapone Orion may increase the effects and side effects of certain medicines.
Zdravilo Levodopa/Carbidopa/Entacapone Orion lahko poveča učinke in neželene učinke določenih zdravil.